Athira Pharma is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Athira’s mission is to harness the power of the neurotrophic hepatocyte growth factor (HGF) system to protect and repair neuronal networks. With a deep knowledge base, broad intellectual property, and a robust pipeline of proprietary small molecules, Athira aims to develop potentially first-in-class and next-generation therapies that offer hope to patients suffering from conditions such as Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis (ALS).

Latest News

Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease

Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates

Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)

Athira Webinar Event

Watch Athira Webinar

About Us

Why Athira?

Athira is distinguished by its unique approach to neurodegenerative disease treatment. Athira is focused on developing therapeutics that enhance the naturally occurring neurotrophic HGF system, which is critical to normal brain function and may play a key role in maintaining the health and functioning of neuronal networks. With an experienced leadership team, Athira is well-positioned to advance its groundbreaking therapies through clinical development and into the hands of patients in need.

Download Athira's Deck

Company Highlights:

Topline Clinical Data: Athira is targeting to release topline data from the late-stage clinical trial of fosgonimeton for Alzheimer’s disease by the end of September. An unblinded interim analysis recommended continuing the trial, bolstering Athira's confidence in a favorable outcome.
Potential of Fosgonimeton: Athira believes fosgonimeton has the potential to improve cognition and function to help improve the lives of the millions of people suffering from AD who currently have limited therapeutic options.
Strong Financial Position: Trading near cash, Athira has a strong balance sheet capable of supporting clinical programs through key inflection points.

Athira's Growth Plan

Athira is focused on advancing its clinical pipeline with a near-term emphasis on fosgonimeton for Alzheimer's disease. The Phase 2/3 LIFT-AD trial has treated the last patient in the trial and topline data is now targeted for release by the end of September 2024, with those results to be presented orally at the Clinical Trials on Alzheimer’s Disease conference (CTAD) on October 29, 2024, in Madrid, Spain.

Beyond fosgonimeton, Athira is advancing ATH-1105, a next-generation, orally administered, small molecule drug candidate in development for the potential treatment of ALS. ATH-1105 is currently being evaluated in a Phase 1 clinical trial in healthy volunteers. In preclinical models of ALS, ATH-1105 has been shown to significantly increase survival, enhance motor and nerve function, reduce peripheral nerve demyelination and axon degeneration, and improve neurodegeneration and inflammation.